Clinical studies demonstrated that MALAT1 was correlated with clinical progression and unfavorable prognosis in pancreatic cancer and that patients with higher expression of MALAT1 had a poorer disease free survival compared to patients with low expression of MALAT1 [63,100]. This evidence concerns the gene MALAT1 and pancreatic neoplasm.